Orfadin (Nitisinone) Patent Expiration, LOE Window & CMS Spending

Orfadin (Nitisinone) by Swedish Orphan Biovitrum Ab Publ: FDA Orange Book LOE 2033-02-28, 3 AB generics, $14.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSwedish Orphan Biovitrum Ab Publ
FDA Application & PathwayN021232 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-02-28
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$14.2M
2024 Medicare Part D Spend$243K
2024 Medicaid Spend$14.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel